Cargando…

Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents

BACKGROUND: Duration of post‐vaccination protection against COVID‐19 in nursing home (NH) residents is a critical issue. The objective of this study was to estimate the duration of the IgG(S) response to the mRNA BNT162b2 vaccine in NH residents with (COV‐Yes) or without (COV‐No) history of SARS‐CoV...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeulin, Helene, Labat, Carlos, Duarte, Kevin, Toupance, Simon, Nadin, Gregoire, Craus, Denis, Georgiopoulos, Ioannis, Gantois, Isabelle, Goehringer, François, Benetos, Athanase
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115082/
https://www.ncbi.nlm.nih.gov/pubmed/35484977
http://dx.doi.org/10.1111/jgs.17837
_version_ 1784709899093016576
author Jeulin, Helene
Labat, Carlos
Duarte, Kevin
Toupance, Simon
Nadin, Gregoire
Craus, Denis
Georgiopoulos, Ioannis
Gantois, Isabelle
Goehringer, François
Benetos, Athanase
author_facet Jeulin, Helene
Labat, Carlos
Duarte, Kevin
Toupance, Simon
Nadin, Gregoire
Craus, Denis
Georgiopoulos, Ioannis
Gantois, Isabelle
Goehringer, François
Benetos, Athanase
author_sort Jeulin, Helene
collection PubMed
description BACKGROUND: Duration of post‐vaccination protection against COVID‐19 in nursing home (NH) residents is a critical issue. The objective of this study was to estimate the duration of the IgG(S) response to the mRNA BNT162b2 vaccine in NH residents with (COV‐Yes) or without (COV‐No) history of SARS‐CoV‐2 infection. METHODS: A 574 COV‐Yes and COV‐No NH residents were included in 2 cohorts: Main (n = 115, median age 87 years) or Confirmatory (n = 459, median age 89 years). IgG(S) quantification was carried out at three different time points following the BNT162b2 vaccine: three (1st) and seven (2nd) months after the 2nd dose, and 1 month after the 3rd dose (3rd quantification) in the Main cohort, and twice (2nd and 3rd) in the Confirmatory cohort. The seroneutralization capacity according to COVID‐19 history was also measured in a subgroup of patients. RESULTS: Neutralization capacity was strongly correlated with IgG(S) levels (R (2):76%) without any difference between COV‐Yes and COV‐No groups for the same levels of IgG(S). After the 2nd dose, duration of the assumed robust protection (IgG(S) >264 BAU/ml) was two‐fold higher in the COV‐Yes vs. COV‐No group: 12.60 (10.69–14.44) versus 5.76 (3.91–8.64) months, with this advantage mainly due to the higher IgG(S) titers after the 2nd dose and secondary to a slower decay over time. After the 3rd dose, duration of robust protection was estimated at 11.87 (9.88–14.87) (COV‐Yes) and 8.95 (6.85–11.04) (COV‐No) months. These results were similar in both cohorts. CONCLUSIONS AND RELEVANCE: In old subjects living in NH, history of SARS‐CoV‐2 infection provides a clear advantage in the magnitude and duration of high IgG(S) titers following the 2nd dose. Importantly, the 3rd dose induces a much more pronounced IgG(S) response than the 2nd dose in COV‐No subjects, the effect of which should be able to ensure a prolonged protection against severe forms of COVID‐19 in these subjects.
format Online
Article
Text
id pubmed-9115082
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-91150822022-05-18 Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents Jeulin, Helene Labat, Carlos Duarte, Kevin Toupance, Simon Nadin, Gregoire Craus, Denis Georgiopoulos, Ioannis Gantois, Isabelle Goehringer, François Benetos, Athanase J Am Geriatr Soc Clinical Investigations BACKGROUND: Duration of post‐vaccination protection against COVID‐19 in nursing home (NH) residents is a critical issue. The objective of this study was to estimate the duration of the IgG(S) response to the mRNA BNT162b2 vaccine in NH residents with (COV‐Yes) or without (COV‐No) history of SARS‐CoV‐2 infection. METHODS: A 574 COV‐Yes and COV‐No NH residents were included in 2 cohorts: Main (n = 115, median age 87 years) or Confirmatory (n = 459, median age 89 years). IgG(S) quantification was carried out at three different time points following the BNT162b2 vaccine: three (1st) and seven (2nd) months after the 2nd dose, and 1 month after the 3rd dose (3rd quantification) in the Main cohort, and twice (2nd and 3rd) in the Confirmatory cohort. The seroneutralization capacity according to COVID‐19 history was also measured in a subgroup of patients. RESULTS: Neutralization capacity was strongly correlated with IgG(S) levels (R (2):76%) without any difference between COV‐Yes and COV‐No groups for the same levels of IgG(S). After the 2nd dose, duration of the assumed robust protection (IgG(S) >264 BAU/ml) was two‐fold higher in the COV‐Yes vs. COV‐No group: 12.60 (10.69–14.44) versus 5.76 (3.91–8.64) months, with this advantage mainly due to the higher IgG(S) titers after the 2nd dose and secondary to a slower decay over time. After the 3rd dose, duration of robust protection was estimated at 11.87 (9.88–14.87) (COV‐Yes) and 8.95 (6.85–11.04) (COV‐No) months. These results were similar in both cohorts. CONCLUSIONS AND RELEVANCE: In old subjects living in NH, history of SARS‐CoV‐2 infection provides a clear advantage in the magnitude and duration of high IgG(S) titers following the 2nd dose. Importantly, the 3rd dose induces a much more pronounced IgG(S) response than the 2nd dose in COV‐No subjects, the effect of which should be able to ensure a prolonged protection against severe forms of COVID‐19 in these subjects. John Wiley & Sons, Inc. 2022-05-10 /pmc/articles/PMC9115082/ /pubmed/35484977 http://dx.doi.org/10.1111/jgs.17837 Text en Journal of the American Geriatrics Society© 2022 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Investigations
Jeulin, Helene
Labat, Carlos
Duarte, Kevin
Toupance, Simon
Nadin, Gregoire
Craus, Denis
Georgiopoulos, Ioannis
Gantois, Isabelle
Goehringer, François
Benetos, Athanase
Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
title Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
title_full Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
title_fullStr Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
title_full_unstemmed Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
title_short Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
title_sort anti‐spike igg antibody kinetics following the second and third doses of bnt162b2 vaccine in nursing home residents
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115082/
https://www.ncbi.nlm.nih.gov/pubmed/35484977
http://dx.doi.org/10.1111/jgs.17837
work_keys_str_mv AT jeulinhelene antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents
AT labatcarlos antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents
AT duartekevin antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents
AT toupancesimon antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents
AT nadingregoire antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents
AT crausdenis antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents
AT georgiopoulosioannis antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents
AT gantoisisabelle antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents
AT goehringerfrancois antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents
AT benetosathanase antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents